OncoMatch/Clinical Trials/NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Is NCT06315491 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CBX-12 for platinum-resistant ovarian cancer.
Treatment: CBX-12 — The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum. Patients who have progressed following a second course of a platinum based regimen.
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: biologic agent
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: investigational agent
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: radiation therapy
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Arizona Oncology Associates · Tucson, Arizona
- Usc Norris Comprehensive Cancer Center · Los Angeles, California
- Yale University School of Medicine · New Haven, Connecticut
- D&H Cancer Research Center · Margate, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify